Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Disseminated cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Disseminated cancer. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-000758-37 Sponsor Protocol Number: NO18517 Start Date*: 2016-08-23
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas
    Medical condition: High Grade Glioma Brainstem Glioma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004529-22 Sponsor Protocol Number: D3465C00001 Start Date*: 2021-08-24
    Sponsor Name:AstraZeneca
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus
    Medical condition: Moderate-to-severe Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BG (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001039-11 Sponsor Protocol Number: GA30044 Start Date*: 2016-11-16
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) ES (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001270-33 Sponsor Protocol Number: GCTSK003 Start Date*: 2015-07-28
    Sponsor Name:Národný onkologický ústav
    Full Title: A treatment strategy of the Use of 1st line Chemotherapy in Patients with Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors based on tumor marker decline: A Phase II Trial of paclitaxel...
    Medical condition: Disseminated Non-Seminomatous Germ Cell Tumors.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2018-005038-39 Sponsor Protocol Number: Start Date*: 2020-12-02
    Sponsor Name:Queen Mary University of London
    Full Title: ChariotMS – A national (UK), multi-centre, randomised, double-blind, placebo-controlled (1:1) phase IIb efficacy trial with cost-utility analysis of cladribine tablets (3.5mg/kg over two years) in ...
    Medical condition: Advanced Multiple Sclerosis (EDSS 6.5-8.5)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10052785 Multiple sclerosis acute and progressive HLT
    20.1 10029205 - Nervous system disorders 10078558 Multiple sclerosis plaque LLT
    22.1 10029205 - Nervous system disorders 10028246 Multiple sclerosis aggravated LLT
    20.1 10028245 - Multiple sclerosis 10078559 Multiple sclerosis brain lesion LLT
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10064137 Progression of multiple sclerosis LLT
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-002667-34 Sponsor Protocol Number: WA39085 Start Date*: 2020-03-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLE...
    Medical condition: Relapsing-remitting multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023103-94 Sponsor Protocol Number: 002:CD40L Start Date*: 2011-07-04
    Sponsor Name:Uppsala University
    Full Title: PHASE I/IIa AdCD40L IMMUNOGENE THERAPY FOR MALIGNANT MELANOMA PATIENTS WITH DISSEMINATED DISEASE
    Medical condition: malignant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002665-35 Sponsor Protocol Number: 190619 Start Date*: 2019-10-14
    Sponsor Name:Mikkel Holm Vendelbo
    Full Title: 16α-18F-fluor-17β-estradiol PET/CT for detection of estrogen receptor positive liver metastases in breast cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001948-21 Sponsor Protocol Number: GETHI-2011-03 Start Date*: 2012-08-17
    Sponsor Name:Grupo Español de Tumores Huérfanos e Infrecuentes
    Full Title: Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study.
    Medical condition: Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057376 Ovarian granulosa-theca cell tumour PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023396-25 Sponsor Protocol Number: SM101-201-sle-10 Start Date*: 2011-09-22
    Sponsor Name:SuppreMol GmbH
    Full Title: Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble F...
    Medical condition: Systemic lupus erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005760-57 Sponsor Protocol Number: CA42750 Start Date*: 2021-08-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014446-28 Sponsor Protocol Number: JANUS Start Date*: 2009-12-03
    Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO
    Full Title: A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER
    Medical condition: invasive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036917 Prostate cancer stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001392-21 Sponsor Protocol Number: P018.087 Start Date*: 2018-09-25
    Sponsor Name:Leiden University Medical Center
    Full Title: A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythematosus
    Medical condition: systemic lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10042947 Systemic lupus erythematosus synd LLT
    20.0 100000004857 10029142 Nephritis systemic lupus erythematosus LLT
    21.1 100000004859 10042948 Systemic lupus erythematosus syndrome aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024111-13 Sponsor Protocol Number: AIO-STO-0110 Start Date*: 2011-04-15
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy
    Medical condition: Gastric adenocarcinoma and carcinoma of the esophago-gastric junction (type II and type III according to Siewert’s classification) prior to gastrectomy, with peritoneal carcinomatosis.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068069 Peritoneal carcinomatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000882-34 Sponsor Protocol Number: AGO/2014/002 Start Date*: 2014-06-03
    Sponsor Name:University Hospital Ghent
    Full Title: Catheter based adjuvant intraperitoneal chemotherapy for carcinomatosis.
    Medical condition: carcinomatosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10007506 Carcinomatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005345-50 Sponsor Protocol Number: RD-FCH-2014 Start Date*: 2015-04-21
    Sponsor Name:Masarykův onkologický ústav
    Full Title: Diagnostic feasibility and morfological and functional correlation of PET examination in use of [18F]-Fluorocholin inj. in patients with prostate cancer
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-006068-99 Sponsor Protocol Number: DuoNen2020 Start Date*: 2021-09-20
    Sponsor Name:Narodowe Centrum Badań Jądrowych, Ośrodek Radioizotopów POLATOM
    Full Title: Tandem therapy LutaPol/ItraPol (177Lu / 90Y-DOTATATE) as an effective method in the treatment of neuroendocrine neoplasms, Acronym: DuoNen, 2019 / ABM / 01/00077
    Medical condition: Diagnosed and confirmed histopathologically disseminated or locally unresectable, well and moderately differentiated (G1 and G2) neuroendocrine neoplasms of the gastrointestinal tract (GEP-NET)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005306-11 Sponsor Protocol Number: SleepRCT_270215 Start Date*: 2016-06-09
    Sponsor Name:St. Olavs Hospital, trondheim University Hospital
    Full Title: Pharmacological treatment of insomnia in palliative care A randomized, double-blind, placebo controlled, parallel-group, multicenter trial investigating the short time effectiveness of zopiclone...
    Medical condition: The overall aim of this clinical trial is to improve the knowledge of the pharmacological treatment of insomnia in patients with advanced cancer who use opioids. Despite the high prevalence of inso...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-001393-19 Sponsor Protocol Number: 003:TCELL Start Date*: 2014-04-08
    Sponsor Name:Uppsala university
    Full Title: CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy - a phase I/IIa trial.
    Medical condition: CD19+ B cell lymphoma or leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000353-39 Sponsor Protocol Number: CONFRONT Start Date*: 2018-05-02
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: The CONFRONT Phase I – II Trial: ACtivatiON oF immune RespONse in paTients with R-M Head and Neck Cancer. Multimodality immunotherapy with Avelumab, short course radiotherapy and Cyclophosphamide i...
    Medical condition: R-M Head and Neck Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034813 Pharyngeal cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055104 Pharyngeal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 06:08:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA